Last year, Amgen Inc generated 7.26B USD for its biggest-performing segment, Other products. The US made the largest contribution, accounting for 25.66B USD last year. For the latest quarter, Amgen Inc reported the revenue of 1.70B USD for the period ending 2026-06-30, which came from the top-performing segment, Other products. US contributed the highest revenue, at 6.44B USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Other products

Prolia

Repatha

Otezla

Enbrel

XGEVA

TEPEZZA

Other revenues

EVENITY- US

BLINCYTO

Nplate

TEZSPIRE

KYPROLIS

Aranesp

KRYSTEXXA

Vectibix

EVENITY- ROW

Neulasta

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Other products

7.26B(19.76%)

5.63B(16.84%)

5.26B(18.67%)

5.22B(19.83%)

5.85B(22.52%)

6.57B(25.86%)

5.54B(23.71%)

5.57B(23.46%)

Prolia

4.41B(12.01%)

4.37B(13.09%)

4.05B(14.36%)

3.63B(13.78%)

3.25B(12.50%)

2.76B(10.87%)

2.67B(11.44%)

2.29B(9.65%)

Repatha

3.02B(8.21%)

2.22B(6.65%)

1.64B(5.80%)

1.30B(4.92%)

1.12B(4.30%)

887.00M(3.49%)

661.00M(2.83%)

550.00M(2.32%)

Otezla

2.27B(6.16%)

2.13B(6.36%)

2.19B(7.76%)

2.29B(8.69%)

2.25B(8.66%)

2.19B(8.63%)

178.00M(0.76%)

--(--)

Enbrel

2.23B(6.06%)

3.32B(9.92%)

3.70B(13.11%)

4.12B(15.64%)

4.46B(17.19%)

5.00B(19.65%)

5.23B(22.37%)

5.01B(21.11%)

XGEVA

2.08B(5.67%)

2.23B(6.66%)

2.11B(7.49%)

2.01B(7.65%)

2.02B(7.77%)

1.90B(7.47%)

1.94B(8.28%)

1.79B(7.52%)

TEPEZZA

1.90B(5.18%)

1.85B(5.54%)

448.00M(1.59%)

--(--)

Other revenues

1.60B(4.36%)

1.40B(4.18%)

1.28B(4.54%)

1.52B(5.78%)

1.68B(6.47%)

1.18B(4.66%)

1.16B(4.96%)

1.21B(5.11%)

EVENITY- US

1.60B(4.35%)

1.13B(3.38%)

809.00M(2.87%)

533.00M(2.02%)

--(--)

BLINCYTO

1.56B(4.24%)

1.22B(3.64%)

861.00M(3.05%)

583.00M(2.21%)

--(--)

Nplate

1.52B(4.15%)

1.46B(4.36%)

1.48B(5.24%)

1.31B(4.97%)

1.03B(3.95%)

--(--)

TEZSPIRE

1.48B(4.02%)

972.00M(2.91%)

--(--)

KYPROLIS

1.41B(3.84%)

1.50B(4.50%)

1.40B(4.98%)

1.25B(4.74%)

1.11B(4.26%)

1.06B(4.19%)

1.04B(4.47%)

968.00M(4.08%)

Aranesp

1.39B(3.78%)

1.34B(4.02%)

1.36B(4.83%)

1.42B(5.40%)

1.48B(5.70%)

1.57B(6.17%)

1.73B(7.40%)

1.88B(7.90%)

KRYSTEXXA

1.34B(3.65%)

1.19B(3.55%)

272.00M(0.96%)

--(--)

Vectibix

1.18B(3.20%)

1.04B(3.13%)

984.00M(3.49%)

893.00M(3.39%)

--(--)

EVENITY- ROW

500.00M(1.36%)

432.00M(1.29%)

351.00M(1.25%)

254.00M(0.96%)

--(--)

Neulasta

--(--)

1.73B(6.67%)

2.29B(9.02%)

3.22B(13.79%)

4.47B(18.84%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

ROW

Other revenues

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

25.66B(69.81%)

23.30B(69.71%)

19.27B(68.36%)

18.06B(66.75%)

17.29B(66.54%)

17.98B(70.74%)

17.22B(70.24%)

ROW

9.49B(25.83%)

8.72B(26.10%)

7.64B(27.09%)

7.47B(27.62%)

7.01B(26.99%)

6.25B(24.60%)

6.14B(25.03%)

Other revenues

1.60B(4.36%)

1.40B(4.18%)

1.28B(4.54%)

1.52B(5.62%)

1.68B(6.47%)

1.18B(4.66%)

1.16B(4.72%)